194 related articles for article (PubMed ID: 30237107)
1. Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.
Kaye AE; Hawkes ED; Gout II; El-Amir AN; Neffendorf JE
Mult Scler Relat Disord; 2018 Nov; 26():74-76. PubMed ID: 30237107
[TBL] [Abstract][Full Text] [Related]
2. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
4. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
5. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
[No Abstract] [Full Text] [Related]
10. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
11. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
Almeida KJ; Barreto-Soares RV; Campos-Sousa RN; Campos-Sousa MG; Bor-Seng-Shu E
Mult Scler; 2018 Jun; 24(7):1002-1004. PubMed ID: 29649930
[TBL] [Abstract][Full Text] [Related]
14. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
Fernández O; García-Merino JA; Arroyo R; Álvarez-Cermeño JC; Izquierdo G; Saiz A; Olascoaga J; Rodríguez-Antigüedad A; Prieto JM; Oreja-Guevara C; Hernández MA; Moral E; Meca J; Montalbán X
Neurologia; 2015 Jun; 30(5):302-14. PubMed ID: 24360652
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
[No Abstract] [Full Text] [Related]
16. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
17. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
Yap SM; McGuigan C
Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
[No Abstract] [Full Text] [Related]
18. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
Clerico M; Artusi CA; Di Liberto A; Rolla S; Bardina V; Barbero P; De Mercanti SF; Durelli L
Expert Opin Drug Saf; 2017 Aug; 16(8):963-972. PubMed ID: 28641055
[TBL] [Abstract][Full Text] [Related]
19. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
[TBL] [Abstract][Full Text] [Related]
20. Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Foley RW; Tagg NT; Schindler MK; Fenton KM; Reich DS; Cortese I; Mowry EM
Mult Scler; 2017 Sep; 23(10):1424-1427. PubMed ID: 28639536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
